Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Unigene Laboratories Inc (UGNE) since 2010 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Unigene Laboratories Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 352747.
Total stock buying since 2010: $509,562.
Total stock sales since 2010: $0.
Total stock option exercises since 2010: $99,975.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2011 | 163,900 | $97,376 | 0 | $0 | 85,000 | $29,475 |
| 2010 | 594,650 | $412,186 | 0 | $0 | 150,000 | $70,500 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2011-12 | 163,900 | $97,376 | 0 | $0 | 0 | $0 |
| 2011-06 | 0 | $0 | 0 | $0 | 85,000 | $29,475 |
| 2010-12 | 266,100 | $193,441 | 0 | $0 | 150,000 | $70,500 |
| 2010-09 | 20,800 | $14,709 | 0 | $0 | 0 | $0 |
| 2010-08 | 286,550 | $187,394 | 0 | $0 | 0 | $0 |
| 2010-06 | 21,200 | $16,642 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2011-12-21 | Thomas Jenene D. (VP of Investor Relations) | Buy | 2,000 | .53 | 1,050 |
| 2011-12-21 | Tavakkol Roxanne (VP, Global Regulatory Affairs) | Buy | 1,500 | .64 | 952 |
| 2011-12-21 | Tune Joel A. (Director) | Buy | 15,000 | .56 | 8,475 |
| 2011-12-21 | Palmer Ashleigh (President & CEO) | Buy | 10,000 | .53 | 5,280 |
| 2011-12-21 | Mayes, Gregory T. (VP, Corp Development and GC) | Buy | 2,000 | .53 | 1,050 |
| 2011-12-21 | Odlaug Theron Edwin (Director) | Buy | 10,000 | .53 | 5,300 |
| 2011-12-21 | Advanced Life Sciences Holdings, Inc. (Director) | Buy | 10,000 | .53 | 5,300 |
| 2011-12-21 | Mehta Nozer (VP, Biological R&D) | Buy | 1,400 | .54 | 749 |
| 2011-12-21 | Shields Paul (Vice Pres. Mfg. Operations) | Buy | 2,000 | .53 | 1,050 |
| 2011-12-21 | Sabatino Thomas J Jr (Director) | Buy | 100,000 | .63 | 62,900 |
| 2011-12-21 | Zvi Eiref (Director) | Buy | 10,000 | .53 | 5,270 |
| 2011-06-20 | Bloom Allen (Director) | Option Ex | 10,000 | .66 | 6,600 |
| 2011-06-14 | Mehta Nozer (Vice Pres. Biological R&D) | Option Ex | 75,000 | .30 | 22,875 |
| 2010-12-22 | Levy Richard N (Director) | Buy | 50,000 | .74 | 37,000 |
| 2010-12-21 | Levy Richard N (Director) | Buy | 50,000 | .75 | 37,500 |
| 2010-12-21 | Zvi Eiref (Director) | Buy | 5,000 | .72 | 3,600 |
| 2010-12-20 | Levy Richard N (Director) | Buy | 50,000 | .75 | 37,500 |
| 2010-12-20 | Zvi Eiref (Director) | Buy | 10,000 | .73 | 7,300 |
| 2010-12-17 | Levy Richard N (Director) | Buy | 26,100 | .72 | 18,792 |
| 2010-12-17 | Bloom Allen (Director) | Option Ex | 150,000 | .47 | 70,500 |
| 2010-12-15 | Levy Richard N (Director) | Buy | 75,000 | .69 | 51,749 |
| 2010-09-21 | Steinhauer William Jacob (Vice President of Finance) | Buy | 5,000 | .69 | 3,449 |
| 2010-09-20 | Palmer Ashleigh (President & CEO) | Buy | 8,800 | .70 | 6,160 |
| 2010-09-03 | Levy Richard N (Director) | Buy | 5,000 | .72 | 3,600 |
| 2010-09-03 | Slusser Peter (Director) | Buy | 2,000 | .75 | 1,500 |
| 2010-08-31 | Levy Richard N (Director) | Buy | 50,000 | .70 | 35,000 |
| 2010-08-30 | Levy Richard N (Director) | Buy | 18,917 | .68 | 12,863 |
| 2010-08-27 | Levy Richard N (Director) | Buy | 176,633 | .65 | 114,811 |
| 2010-08-17 | Zvi Eiref (Director) | Buy | 17,000 | .60 | 10,200 |
| 2010-08-16 | Zvi Eiref (Director) | Buy | 4,000 | .63 | 2,520 |
| 2010-08-12 | Palmer Ashleigh (President & CEO) | Buy | 20,000 | .60 | 12,000 |
| 2010-06-18 | Palmer Ashleigh (President & CEO) | Buy | 21,200 | .79 | 16,642 |
Insider trading activities including stock purchases, stock sales, and option exercises of UGNE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Unigene Laboratories Inc (symbol UGNE, CIK number 352747) see the Securities and Exchange Commission (SEC) website.